Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Prevention and risk

Topic: Risk, prevention and care in population studies

Plain-language summary

Age-related hearing loss (ARHL) has emerged as a significant and potentially modifiable risk factor for neurodegenerative disorders, including Alzheimer's disease. A growing body of evidence links ARHL to structural and functional changes in the brain, with implications for cognitive decline and dementia onset. However, both ARHL and dementia are multifactorial conditions shaped not only by biological mechanisms but also by broader social determinants of health. Inequities in access to hearing care, underrepresentation of marginalised populations in research, and variability in intervention outcomes emphasise the need for a more inclusive and integrated approach to prevention. This review synthesises current evidence on the neurocognitive consequences of ARHL, the potential mechanistic pathways linking hearing loss to dementia, and the role of inequity. It includes a novel perspective by highlighting the need for cross-cultural, population neuroscience approaches incorporating exposome and equity frameworks that capture phenotypic variability across diverse populations. This review outlines key priorities for advancing neurocognitive and translational research on hearing loss, neurodegeneration, and global health equity. Addressing these gaps is essential to developing equitable strategies for dementia prevention and optimising cognitive health across the lifespan.

What this study adds

Evidence grade: Low

This review describes age-related hearing loss as a potentially modifiable risk factor for neurodegenerative disorders including Alzheimer's disease, and discusses possible mechanisms and inequities in hearing care. It outlines research priorities rather than testing any treatment or prevention, so it does not show that treating hearing loss prevents dementia.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Loughrey, D. G. (2025). Age-related hearing loss and dementia risk across the lifespan: mechanisms, equity, and prevention. Neuroscience. https://doi.org/10.1016/j.neuroscience.2025.08.056

Vancouver

Loughrey DG. Age-related hearing loss and dementia risk across the lifespan: mechanisms, equity, and prevention. Neuroscience. 2025. doi:10.1016/j.neuroscience.2025.08.056. PMID: 40885376.

BibTeX

@article{loughrey2025-40885376,
  author  = {Loughrey, David G.},
  title   = {{Age-related hearing loss and dementia risk across the lifespan: mechanisms, equity, and prevention}},
  journal = {Neuroscience},
  year    = {2025},
  doi     = {10.1016/j.neuroscience.2025.08.056},
  pmid    = {40885376},
  url     = {https://doi.org/10.1016/j.neuroscience.2025.08.056}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review describes age-related hearing loss as a potentially modifiable risk factor for neurodegenerative disorders including Alzheimer's disease, and discusses possible mechanisms and inequities in hearing care. It outlines research priorities rather than testing any treatment or prevention, so it does not show that treating hearing loss prevents dementia.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neuroscience)
Journal's citation record 3 / 4 Neuroscience: journal h-index 370 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 7 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.3 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 4.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author David G. Loughrey: h-index 11 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40885376)
Free to read 2 / 2 Free to read
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.

Related studies in Prevention and risk from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →